Mars Fishcare North America, Inc.

Chemwatch: 4658-75

Version No: 7.1 Safety Data Sheet according to OSHA HazCom Standard (2012) requirements

SECTION 1 Identification

Product Identifier	
Product name	EM Powder Medication
Chemical Name	Not Applicable
Synonyms	Not Available
Chemical formula	Not Applicable
Other means of identification	Not Available
Other means of identification	Not Available

Recommended use of the chemical and restrictions on use

Name, address, and telephone number of the chemical manufacturer, importer, or other responsible party

Registered company name	Mars Fishcare North America, Inc.
Address	50 E. Hamilton Street, Chalfont PA 18914 United States
Telephone	215 822 8181
Fax	215 997 1290
Website	Not Available
Email	Not Available

Emergency phone number

Association / Organisation	ChemTel	CHEMWATCH EMERGENCY RESPONSE (24/7)
Emergency telephone numbers	1-800-255-3924	+1 855-237-5573
Other emergency telephone numbers	ChemTel: 1-813-248-0585	+61 3 9573 3188


Once connected and if the message is not in your preferred language then please dial 01

Una vez conectado y si el mensaje no está en su idioma preferido, por favor marque 02

SECTION 2 Hazard(s) identification

Classification of the substance or mixture

NFPA 704 diamond



Warning

Signal word

Hazard statement(s)

nazaru statement(s)	
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H335	May cause respiratory irritation.

Chemwatch Hazard Alert Code: 2

Issue Date: 03/10/2023 Print Date: 09/18/2023 L.GHS.USA.EN

Hazard(s) not otherwise classified

Not Applicable

Precautionary statement(s) Prevention

P271	Use only outdoors or in a well-ventilated area.
P261	Avoid breathing dust/fumes.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P264	Wash all exposed external body areas thoroughly after handling.

Precautionary statement(s) Response

P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P312	Call a POISON CENTER/doctor/physician/first aider/if you feel unwell.
P337+P313	If eye irritation persists: Get medical advice/attention.
P302+P352	IF ON SKIN: Wash with plenty of water.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P332+P313	If skin irritation occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.

Precautionary statement(s) Storage

P405	Store locked up.
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
7647-14-5	>80	sodium chloride
4501-00-2	1-10	erythromycin phosphate
112945-52-5	1-5	silica amorphous, fumed, crystalline free

SECTION 4 First-aid measures

Description of first aid measures

Eye Contact	 If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	 If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	 If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary.
Ingestion	 Immediately give a glass of water. First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.

Most important symptoms and effects, both acute and delayed

See Section 11

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 Fire-fighting measures

Extinguishing media

There is no restriction on the type of extinguisher which may be used.

Use extinguishing media suitable for surrounding area.

Special hazards arising from the substrate or mixture

Special protective equipment and precautions for fire-fighters

None known.

Fire Incompatibility

Special protective equipment and precautions for file-fighters		
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. 	
Fire/Explosion Hazard	 Non combustible. Not considered a significant fire risk, however containers may burn. Decomposition may produce toxic fumes of: nitrogen oxides (NOx) metal oxides May emit poisonous fumes. May emit corrosive fumes. hydrogen chloride 	

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	 Clean up all spills immediately. Avoid breathing dust and contact with skin and eyes. Wear protective clothing, gloves, safety glasses and dust respirator. Use dry clean up procedures and avoid generating dust. Sweep up, shovel up or Vacuum up (consider explosion-proof machines designed to be grounded during storage and use). Place spilled material in clean, dry, sealable, labelled container.
Major Spills	 Moderate hazard. CAUTION: Advise personnel in area. Alert Emergency Services and tell them location and nature of hazard. Control personal contact by wearing protective clothing. Control personal contact by wearing protective clothing. Prevent, by any means available, spillage from entering drains or water courses. Recover product wherever possible. IF DRY: Use dry clean up procedures and avoid generating dust. Collect residues and place in sealed plastic bags or other containers for disposal. IF WET: Vacuum/shovel up and place in labelled containers for disposal. ALWAYS: Wash area down with large amounts of water and prevent runoff into drains. If contamination of drains or waterways occurs, advise Emergency Services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling	
Safe handling	 Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps. DO NOT enter confined spaces until atmosphere has been checked. DO NOT allow material to contact humans, exposed food or food utensils. Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. Work clothes should be laundered separately. Launder contaminated clothing before re-use. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Other information	 Store in original containers. Keep containers securely sealed. Store in a cool, dry area protected from environmental extremes. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. Observe manufacturer's storage and handling recommendations contained within this SDS. For major quantities: Consider storage in bunded areas - ensure storage areas are isolated from sources of community water (including stormwater, ground water, lakes and streams). Ensure that accidental discharge to air or water is the subject of a contingency disaster management plan; this may require consultation with local authorities.

Conditions for safe storage, including any incompatibilities

Suitable container	 Polyethylene or polypropylene container. Check all containers are clearly labelled and free from leaks.
Storage incompatibility	None known

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
US OSHA Permissible Exposure Limits (PELs) Table Z-1	silica amorphous, fumed, crystalline free	Particulates Not Otherwise Regulated (PNOR)- Total dust	15 mg/m3	Not Available	Not Available	Not Available
US OSHA Permissible Exposure Limits (PELs) Table Z-1	silica amorphous, fumed, crystalline free	Particulates Not Otherwise Regulated (PNOR)- Respirable fraction	5 mg/m3	Not Available	Not Available	Not Available
US OSHA Permissible Exposure Limits (PELs) Table Z-3	silica amorphous, fumed, crystalline free	Inert or Nuisance Dust: Respirable fraction	5 mg/m3 / 15 mppcf	Not Available	Not Available	Not Available
US OSHA Permissible Exposure Limits (PELs) Table Z-3	silica amorphous, fumed, crystalline free	Inert or Nuisance Dust: Total Dust	15 mg/m3 / 50 mppcf	Not Available	Not Available	Not Available
US NIOSH Recommended Exposure Limits (RELs)	silica amorphous, fumed, crystalline free	Particulates not otherwise regulated	Not Available	Not Available	Not Available	See Appendix [

Emergency Limits

Ingredient	TEEL-1	TEEL-2		TEEL-3
sodium chloride	0.5 ppm	2 ppm		20 ppm
silica amorphous, fumed, crystalline free	18 mg/m3	100 mg/m3		630 mg/m3
Ingredient	Original IDLH		Revised IDLH	
sodium chloride	Not Available		Not Available	
erythromycin phosphate	Not Available		Not Available	
silica amorphous, fumed, crystalline free	Not Available		Not Available	

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
sodium chloride	E	≤ 0.01 mg/m³
Notes:	Occupational exposure banding is a process of assigning chemicals into s adverse health outcomes associated with exposure. The output of this pro	cess is an occupational exposure band (OEB), which corresponds to a

MATERIAL DATA

Exposure controls

direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active 1-2.5 m/s (200-500		Engineering controls are used to remove a hazard or place a be highly effective in protecting workers and will typically be in The basic types of engineering controls are: Process controls which involve changing the way a job activitien to be a superscript of the two sets and/or isolation of emission source which keeps a "adds" and "removes" air in the work environment. Ventilation ventilation system must match the particular process and che Employers may need to use multiple types of controls to prevent to the proportion will be powdered by mutual friction. If in spite of local exhaust an adverse concentration of the Such protection might consist of: (a): particle dust respirators, if necessary, combined with an a (b): filter respirators with absorption cartridge or canister of the superscript of	ndependent of worker interactions to provide this high level by or process is done to reduce the risk. selected hazard "physically" away from the worker and v in can remove or dilute an air contaminant if designed pro- mical or contaminant in use. vent employee overexposure. Indled as powders or crystals; even when particulates are e substance in air could occur, respiratory protection sho absorption cartridge;	vel of protection. ventilation that strategically perly. The design of a relatively large, a certain
	Appropriate engineering controls	(c): fresh-air hoods or masks. Air contaminants generated in the workplace possess varying circulating air required to effectively remove the contaminant. Type of Contaminant:		re velocities" of fresh Air Speed:
		Air contaminants generated in the workplace possess varying circulating air required to effectively remove the contaminant. Type of Contaminant:		Air Speed:
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion). 2.5-10 m/s (500-2000 f/min.)		Air contaminants generated in the workplace possess varying circulating air required to effectively remove the contaminant. Type of Contaminant: direct spray, spray painting in shallow booths, drum filling, generation into zone of rapid air motion) grinding, abrasive blasting, tumbling, high speed wheel gen	conveyer loading, crusher dusts, gas discharge (active	Air Speed: 1-2.5 m/s (200-500 f/min.) 2.5-10 m/s (500-2000
		Air contaminants generated in the workplace possess varying circulating air required to effectively remove the contaminant. Type of Contaminant: direct spray, spray painting in shallow booths, drum filling, generation into zone of rapid air motion) grinding, abrasive blasting, tumbling, high speed wheel gen of very high rapid air motion).	conveyer loading, crusher dusts, gas discharge (active	Air Speed: 1-2.5 m/s (200-500 f/min.) 2.5-10 m/s (500-2000
of very high rapid air motion). f/min.)		Air contaminants generated in the workplace possess varying circulating air required to effectively remove the contaminant. Type of Contaminant: direct spray, spray painting in shallow booths, drum filling, generation into zone of rapid air motion) grinding, abrasive blasting, tumbling, high speed wheel generation is required air motion). Within each range the appropriate value depends on:	conveyer loading, crusher dusts, gas discharge (active nerated dusts (released at high initial velocity into zone	Air Speed: 1-2.5 m/s (200-500 f/min.) 2.5-10 m/s (500-2000
of very high rapid air motion). f/min.) Within each range the appropriate value depends on:		Air contaminants generated in the workplace possess varying circulating air required to effectively remove the contaminant. Type of Contaminant: direct spray, spray painting in shallow booths, drum filling, generation into zone of rapid air motion) grinding, abrasive blasting, tumbling, high speed wheel gen of very high rapid air motion). Within each range the appropriate value depends on: Lower end of the range	conveyer loading, crusher dusts, gas discharge (active nerated dusts (released at high initial velocity into zone Upper end of the range	Air Speed: 1-2.5 m/s (200-500 f/min.) 2.5-10 m/s (500-2000
of very high rapid air motion). f/min.) Within each range the appropriate value depends on: Lower end of the range Lower end of the range Upper end of the range		Air contaminants generated in the workplace possess varying circulating air required to effectively remove the contaminant. Type of Contaminant: direct spray, spray painting in shallow booths, drum filling, or generation into zone of rapid air motion) grinding, abrasive blasting, tumbling, high speed wheel gen of very high rapid air motion). Within each range the appropriate value depends on: Lower end of the range 1: Room air currents minimal or favourable to capture	conveyer loading, crusher dusts, gas discharge (active nerated dusts (released at high initial velocity into zone Upper end of the range 1: Disturbing room air currents	Air Speed: 1-2.5 m/s (200-500 f/min.) 2.5-10 m/s (500-2000

	4: Large hood or large air mass in motion	4: Small hood-local control only	
	Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 4-10 m/s (800-2000 f/min) for extraction of crusher dusts generated 2 metres distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.		
Individual protection measures, such as personal protective equipment			
Eye and face protection	the wearing of lenses or restrictions on use, should be c and adsorption for the class of chemicals in use and an their removal and suitable equipment should be readily a remove contact lens as soon as practicable. Lens should	equivalent] lenses may absorb and concentrate irritants. A written policy document, describing reated for each workplace or task. This should include a review of lens absorption account of injury experience. Medical and first-aid personnel should be trained in available. In the event of chemical exposure, begin eye irrigation immediately and d be removed at the first signs of eye redness or irritation - lens should be removed in nds thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].	
Skin protection	See Hand protection below		
Hands/feet protection	Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.		
Body protection	See Other protection below		
Other protection	 Overalls. P.V.C apron. Barrier cream. Skin cleansing cream. Eye wash unit. 		

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

EM Powder Medication

Material	CPI
NATURAL RUBBER	А
NATURAL+NEOPRENE	А
NITRILE	А

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type -P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	P1 Air-line*	-	PAPR-P1 -
up to 50 x ES	Air-line**	P2	PAPR-P2
up to 100 x ES	-	P3	-
		Air-line*	-
100+ x ES	-	Air-line**	PAPR-P3

* - Negative pressure demand ** - Continuous flow

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	White powder with no odour; soluble in water.		
Physical state	Divided Solid	Relative density (Water = 1)	1.01
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Applicable
pH (as supplied)	Not Applicable	Decomposition temperature (°C)	Not Available

Melting point / freezing point (°C)	Not Applicable	Viscosity (cSt)	Not Applicable
Initial boiling point and boiling range (°C)	Not Applicable	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Applicable	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Applicable
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Applicable
Vapour pressure (kPa)	Not Applicable	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	Not Applicable
Vapour density (Air = 1)	Not Applicable	VOC g/L	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	 Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

formation on toxicological ef		
Inhaled		irritation of the respiratory tract (as classified by EC Directives using animal osure be kept to a minimum and that suitable control measures be used in an
Ingestion	The material has NOT been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.	
Skin Contact	present twenty-four hours or more after the end of the expo Skin irritation may also be present after prolonged or repeated e dermatitis is often characterised by skin redness (erythema) and thickening of the epidermis. At the microscopic level there may intracellular oedema of the epidermis.	ber of individuals following direct contact, and/or o the healthy intact skin of animals (for up to four hours), such inflammation being
Eye	Examine the skin prior to the use of the material and ensure that Limited evidence or practical experience suggests, that the mat and/or may produce significant ocular lesions which are present	t any external damage is suitably protected. erial may cause moderate eye irritation in a substantial number of individuals twenty-four hours or more after instillation into the eye(s) of experimental
_,,	animals. Repeated or prolonged exposure may cause moderate conjunctiva (conjunctivitis); temporary impairment of vision and/	inflammation (similar to windburn) characterised by a temporary redness of the or other transient eye damage/ulceration may occur.
Chronic	Long term exposure to high dust concentrations may cause changes in lung function (i.e. pneumoconiosis) caused by particles less than 0.5 micron penetrating and remaining in the lung. A prime symptom is breathlessness. Lung shadows show on X-ray. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. Limited evidence shows that inhalation of the material is capable of inducing a sensitisation reaction in a significant number of individuals at a greater frequency than would be expected from the response of a normal population. Pulmonary sensitisation, resulting in hyperactive airway dysfunction and pulmonary allergy may be accompanied by fatigue, malaise and aching. Significant symptoms of exposure may persist for extended periods, even after exposure ceases. Symptoms can be activated by a variety of nonspecific environmental stimuli such as automobile exhaust, perfumes and passive smoking. There exists limited evidence that shows that skin contact with the material is capable either of inducing a sensitisation reaction in a significant number of a significant number of individuals, and/or of producing positive response in experimental animals.	
	тохісіту	IRRITATION
EM Powder Medication	Not Available	Not Available
	ΤΟΧΙΟΙΤΥ	IRRITATION
sodium chloride	Dermal (rabbit) LD50: >10000 mg/kg ^[1]	Eye (rabbit): 10 mg - moderate

	Inhalation(Rat) LC50: >10.5 mg/l4h ^[1]	Eye (rabbit):100	
	Oral (Rat) LD50: 3000 mg/kg ^[2]	Skin (rabbit): 50	10 mg/24h - mild
	ΤΟΧΙΟΙΤΥ	IRRITATION	
erythromycin phosphate	Not Available	Not Available	
		IDDITATION	
silica amorphous, fumed,		IRRITATION Not Available	
crystalline free	Dermal (rabbit) LD50: >5000 mg/kg ^[2]	Not Available	
	Oral (Rat) LD50: 3160 mg/kg ^[2]		
Legend:	 Value obtained from Europe ECHA Registered Substances - A specified data extracted from RTECS - Register of Toxic Effect o 		ined from manufacturer's SDS. Unless otherwise
SODIUM CHLORIDE	Asthma-like symptoms may continue for months or even years a known as reactive airways dysfunction syndrome (RADS) which criteria for diagnosing RADS include the absence of previous air asthma-like symptoms within minutes to hours of a documented airflow pattern on lung function tests, moderate to severe bronch lymphocytic inflammation, without eosinophilia. RADS (or asthma the concentration of and duration of exposure to the irritating subtresult of exposure due to high concentrations of irritating subtarr disorder is characterized by difficulty breathing, cough and mucu The material may produce moderate eye irritation leading to infla conjunctivitis. The material may cause skin irritation after prolonged or repeate dermatitis is often characterised by skin redness (erythema) and spongy layer (spongiosis) and intracellular oedema of the epider	can occur after exposure to vays disease in a non-atop exposure to the irritant. Ot al hyperreactivity on meth by following an irritating inh stance. On the other hance ce (often particles) and is s production. mmation. Repeated or pro- d exposure and may produ swelling epidermis. Histol	to high levels of highly irritating compound. Main pic individual, with sudden onset of persistent her criteria for diagnosis of RADS include a reversibl lacholine challenge testing, and the lack of minimal lalation is an infrequent disorder with rates related to d, industrial bronchitis is a disorder that occurs as a completely reversible after exposure ceases. The plonged exposure to irritants may produce uce a contact dermatitis (nonallergic). This form of
RYTHROMYCIN PHOSPHATE	No significant acute toxicological data identified in literature sear		
	For silica amorphous: Derived No Adverse Effects Level (NOAEL) in the range of 1000 In humans, synthetic amorphous silica (SAS) is essentially non-te evidence of adverse health effects due to SAS. Repeated expose	oxic by mouth, skin or eye	
SILICA AMORPHOUS, FUMED, CRYSTALLINE FREE	drying/cracking of the skin. When experimental animals inhale synthetic amorphous silica (S vast majority of SAS is excreted in the faeces and there is little a via urine without modification in animals and humans. SAS is no After ingestion, there is limited accumulation of SAS in body tisst but appears to be insignificant in animals and humans. SASs inje indication of metabolism of SAS in animals or humans based on soluble in physiological media and the soluble chemical species Both the mammalian and environmental toxicology of SASs are s ⁻ of solubility and particle size. SAS has no acute intrinsic toxicity I were caused by the presence of high numbers of respirable parti representative of exposure to commercial SASs and should not to cause dryness and cracking, SAS is not a skin or eye irritant, and Repeated-dose and chronic toxicity studies confirm the absence Long-term inhalation of SAS caused some adverse effects in ani which subsided after exposure. Numerous repeated-dose, subchronic and chronic inhalation toxi concentrations ranging from 0.5 mg/m3 to 150 mg/m3. Lowest-oi mg/m3. When available, the no-observed adverse effect levels (f explained by different particle size, and therefore the number of p does the NOAEL/LOAEL. Neither inhalation nor oral administration caused neoplasms (tun assays. SAS does not impair development of the foetus. Fertility were not affected. For Synthetic Amorphous Silica (SAS) Repeated dose toxicity Oral (rat), 2 weeks to 6 months, no significant treatment-related a Inhalation (rat), 13 weeks, Lowest Observed Effect Level (LOEL) days, LOEL = 1 mg/m3 based on reversible effects in the lungs a For silane treated synthetic amorphous silica: Repeated dose toxicity: oral (rat), 28-d, diet, no significant treatment There is no evidence of cancer or other long-term respiratory here SAS. Respiratory symptoms in SAS workers have been shown to function values and chest radiographs are not adversely affected	AS) dust, it dissolves in th comulation in the body. F expected to be broken do cted subcutaneously are s chemical structure and av- hat are formed are elimin- ignificantly influenced by thy inhalation. Adverse effec cles generated to meet the re used for human risk ass it is not a sensitiser. of toxicity when SAS is sw mals (increases in lung inf city studies have been cor served adverse effect lev IOAELs) were between 0. particles administered per tours). SAS is not mutage was not specifically studie adverse effects at doses o =1.3 mg/m3 based on mil nd effects (for example, s o correlate with smoking bo	e lung fluid and is rapidly eliminated. If swallowed, the following absorption across the gut, SAS is eliminated own (metabolised) in mammals. soccurs. Intestinal absorption has not been calculated, subjected to rapid dissolution and removal. There is r ailable data. In contrast to crystalline silica, SAS is ated via the urinary tract without modification. the physical and chemical properties, particularly those cts, including suffocation, that have been reported a required test atmosphere. These results are not sessment. Though repeated exposure of the skin may vallowed or upon skin contact. lammation, cell injury and lung collagen content), all o nducted with SAS in a number of species, at airborne els (LOAELs) were typically in the range of 1 to 50 5 and 10 mg/m3. The difference in values may be unit dose. In general, as particle size decreases so nic in vitro. No genotoxicity was detected in in vivo id, but the reproductive organs in long-term studies f up to 8% silica in the diet. Id reversible effects in the lungs. Inhalation (rat), 90 <i>ity</i> . s at the doses tested. illicosis) in workers employed in the manufacture of ut not with SAS exposure, while serial pulmonary
	drying/cracking of the skin. When experimental animals inhale synthetic amorphous silica (S vast majority of SAS is excreted in the faeces and there is little a via urine without modification in animals and humans. SAS is noi After ingestion, there is limited accumulation of SAS in body tisst but appears to be insignificant in animals and humans. SASs inje indication of metabolism of SAS in animals or humans based on soluble in physiological media and the soluble chemical species Both the mammalian and environmental toxicology of SASs are s of solubility and particle size. SAS has no acute intrinsic toxicity I were caused by the presence of high numbers of respirable parti representative of exposure to commercial SASs and should not to cause dryness and cracking, SAS is not a skin or eye irritant, and Repeated-dose and chronic toxicity studies confirm the absence Long-term inhalation of SAS caused some adverse effects in ani which subsided after exposure. Numerous repeated-dose, subchronic and chronic inhalation toxi concentrations ranging from 0.5 mg/m3 to 150 mg/m3. Lowest-o mg/m3. When available, the no-observed adverse effect levels (I explained by different particle size, and therefore the number of p does the NOAEL/LOAEL. Neither inhalation nor oral administration caused neoplasms (tun assays. SAS does not impair development of the foetus. Fertility were not affected. For Synthetic Amorphous Silica (SAS) Repeated dose toxicity Oral (rat), 2 weeks to 6 months, no significant treatment-related a Inhalation (rat), 13 weeks, Lowest Observed Effect Level (LOEL) days, LOEL = 1 mg/m3 based on reversible effects in the lungs a For silane treated synthetic amorphous silica: Repeated dose toxicity: oral (rat), 28-d, diet, no significant treatment There is no evidence of cancer or other long-term respiratory here SAS. Respiratory symptoms in SAS workers have been shown to	AS) dust, it dissolves in the ccumulation in the body. F expected to be broken do cted subcutaneously are a chemical structure and av- hat are formed are elimina- ignificantly influenced by fu- py inhalation. Adverse effect les generated to meet the re used for human risk asse- lit is not a sensitiser. of toxicity when SAS is sw mals (increases in lung inf city studies have been cor oserved adverse effect lev IOAELs) were between 0. ovarticles administered per hours). SAS is not mutage was not specifically studie adverse effects at doses o =1.3 mg/m3 based on mil nd effects in the nasal cav- ent-related adverse effect the ffects (for example, s o correlate with smoking bi- by long-term exposure to	e lung fluid and is rapidly eliminated. If swallowed, th ollowing absorption across the gut, SAS is eliminated own (metabolised) in mammals. yoccurs. Intestinal absorption has not been calculated, subjected to rapid dissolution and removal. There is r ailable data. In contrast to crystalline silica, SAS is ated via the urinary tract without modification. the physical and chemical properties, particularly those cts, including suffocation, that have been reported a required test atmosphere. These results are not sessment. Though repeated exposure of the skin may vallowed or upon skin contact. lammation, cell injury and lung collagen content), all inducted with SAS in a number of species, at airborne rels (LOAELs) were typically in the range of 1 to 50 5 and 10 mg/m3. The difference in values may be unit dose. In general, as particle size decreases so nic in vitro. No genotoxicity was detected in in vivo ed, but the reproductive organs in long-term studies fup to 8% silica in the diet. Id reversible effects in the lungs. Inhalation (rat), 90 <i>v</i> ity. s at the doses tested. illicosis) in workers employed in the manufacture of ut not with SAS exposure, while serial pulmonary SAS.
CRYSTALLINE FREE	drying/cracking of the skin. When experimental animals inhale synthetic amorphous silica (S vast majority of SAS is excreted in the faeces and there is little a via urine without modification in animals and humans. SAS is not After ingestion, there is limited accumulation of SAS in body tisst but appears to be insignificant in animals and humans. SASs inje indication of metabolism of SAS in animals or humans based on soluble in physiological media and the soluble chemical species Both the mammalian and environmental toxicology of SASs are s ⁻ of solubility and particle size. SAS has no acute intrinsic toxicity I were caused by the presence of high numbers of respirable parti representative of exposure to commercial SASs and should not to cause dryness and cracking, SAS is not a skin or eye irritant, and Repeated-dose and chronic toxicity studies confirm the absence Long-term inhalation of SAS caused some adverse effects in ani which subsided after exposure. Numerous repeated-dose, subchronic and chronic inhalation toxi concentrations ranging from 0.5 mg/m3 to 150 mg/m3. Lowest-oi mg/m3. When available, the no-observed adverse effect levels (1 explained by different particle size, and therefore the number of p does the NOAEL/LOAEL. Neither inhalation nor oral administration caused neoplasms (tun assays. SAS does not impair development of the foetus. Fertility were not affected. For Synthetic Amorphous Silica (SAS) Repeated dose toxicity Oral (rat), 2 weeks to 6 months, no significant treatment-related a Inhalation (rat), 13 weeks, Lowest Observed Effect Level (LOEL) days, LOEL = 1 mg/m3 based on reversible effects in the lungs a For silane treated synthetic amorphous silica: Repeated dose toxicity: oral (rat), 28-d, diet, no significant treatment There is no evidence of cancer or other long-term respiratory hea SAS. Respiratory symptoms in SAS workers have been shown to function values and chest radiographs are not adversely affected	AS) dust, it dissolves in th comulation in the body. F expected to be broken do cted subcutaneously are s chemical structure and av- hat are formed are elimin- ignificantly influenced by thy inhalation. Adverse effec cles generated to meet the re used for human risk ass it is not a sensitiser. of toxicity when SAS is sw mals (increases in lung inf city studies have been cor served adverse effect lev IOAELs) were between 0. particles administered per tours). SAS is not mutage was not specifically studie adverse effects at doses o =1.3 mg/m3 based on mil nd effects (for example, s o correlate with smoking bo	e lung fluid and is rapidly eliminated. If swallowed, the following absorption across the gut, SAS is eliminated own (metabolised) in mammals. soccurs. Intestinal absorption has not been calculated, subjected to rapid dissolution and removal. There is r ailable data. In contrast to crystalline silica, SAS is ated via the urinary tract without modification. the physical and chemical properties, particularly those cts, including suffocation, that have been reported a required test atmosphere. These results are not sessment. Though repeated exposure of the skin may vallowed or upon skin contact. lammation, cell injury and lung collagen content), all o nducted with SAS in a number of species, at airborne els (LOAELs) were typically in the range of 1 to 50 5 and 10 mg/m3. The difference in values may be unit dose. In general, as particle size decreases so nic in vitro. No genotoxicity was detected in in vivo id, but the reproductive organs in long-term studies f up to 8% silica in the diet. Id reversible effects in the lungs. Inhalation (rat), 90 <i>ity</i> . s at the doses tested. illicosis) in workers employed in the manufacture of ut not with SAS exposure, while serial pulmonary
CRYSTALLINE FREE Acute Toxicity Skin Irritation/Corrosion	drying/cracking of the skin. When experimental animals inhale synthetic amorphous silica (S vast majority of SAS is excreted in the faeces and there is little a via urine without modification in animals and humans. SAS is not After ingestion, there is limited accumulation of SAS in body tisst but appears to be insignificant in animals and humans. SASs injeindication of metabolism of SAS in animals or humans based on soluble in physiological media and the soluble chemical species Both the mammalian and environmental toxicology of SASs are si of solubility and particle size. SAS has no acute intrinsic toxicity I were caused by the presence of high numbers of respirable parti representative of exposure to commercial SASs and should not b cause dryness and cracking, SAS is not a skin or eye irritant, and Repeated-dose and chronic toxicity studies confirm the absence Long-term inhalation of SAS caused some adverse effects in ani- which subsided after exposure. Numerous repeated-dose, subchronic and chronic inhalation toxic concentrations ranging from 0.5 mg/m3 to 150 mg/m3. Lowest-oi mg/m3. When available, the no-observed adverse effect levels (f explained by different particle size, and therefore the number of p does the NOAEL/LOAEL. Neither inhalation nor oral administration caused neoplasms (turn assays. SAS does not impair development of the foetus. Fertility were not affected. For Synthetic Amorphous Silica (SAS) Repeated dose toxicity Oral (rat), 13 weeks, Lowest Observed Effect Level (LOEL) days, LOEL = 1 mg/m3 based on reversible effects in the lungs a For silane treated synthetic amorphous silica: Repeated dose toxicity: oral (rat), 28-d, diet, no significant treatment There is no evidence of cancer or other long-term respiratory has SAS. Respiratory symptoms in SAS workers have been shown to function values and chest radiographs are not adversely affected	AS) dust, it dissolves in th comulation in the body. F expected to be broken do cted subcutaneously are s chemical structure and av- hat are formed are elimina- ignificantly influenced by thy inhalation. Adverse effec cles generated to meet the re used for human risk ass it is not a sensitiser. of toxicity when SAS is sw mals (increases in lung inf city studies have been cor pserved adverse effect lev IOAELs) were between 0. particles administered per nours). SAS is not mutage was not specifically studies adverse effects at doses o =1.3 mg/m3 based on mil nd effects (for example, s o correlate with smoking by by long-term exposure to Carcinogenicity	e lung fluid and is rapidly eliminated. If swallowed, the following absorption across the gut, SAS is eliminated own (metabolised) in mammals. poccurs. Intestinal absorption has not been calculated, subjected to rapid dissolution and removal. There is r ailable data. In contrast to crystalline silica, SAS is ated via the urinary tract without modification. the physical and chemical properties, particularly tho cts, including suffocation, that have been reported e required test atmosphere. These results are not sessment. Though repeated exposure of the skin mar- vallowed or upon skin contact. lammation, cell injury and lung collagen content), all inducted with SAS in a number of species, at airborne els (LOAELs) were typically in the range of 1 to 50 5 and 10 mg/m3. The difference in values may be unit dose. In general, as particle size decreases so nic in vitro. No genotoxicity was detected in in vivo id, but the reproductive organs in long-term studies f up to 8% silica in the diet. Id reversible effects in the lungs. Inhalation (rat), 90 <i>rity.</i> s at the doses tested. lilicosis) in workers employed in the manufacture of ut not with SAS exposure, while serial pulmonary SAS.
CRYSTALLINE FREE	drying/cracking of the skin. When experimental animals inhale synthetic amorphous silica (S vast majority of SAS is excreted in the faeces and there is little a via urine without modification in animals and humans. SAS is not After ingestion, there is limited accumulation of SAS in body tisss but appears to be insignificant in animals and humans. SASs inje indication of metabolism of SAS in animals or humans based on soluble in physiological media and the soluble chemical species Both the mammalian and environmental toxicology of SASs are s ⁻ of solubility and particle size. SAS has no acute intrinsic toxicity H were caused by the presence of high numbers of respirable parti- representative of exposure to commercial SASs and should not to cause dryness and cracking, SAS is not a skin or eye irritant, and Repeated-dose and chronic toxicity studies confirm the absence Long-term inhalation of SAS caused some adverse effects in ani- which subsided after exposure. Numerous repeated-dose, subchronic and chronic inhalation toxi concentrations ranging from 0.5 mg/m3 to 150 mg/m3. Lowest-oi mg/m3. When available, the no-observed adverse effect levels (f explained by different particle size, and therefore the number of p does the NOAEL/LOAEL. Neither inhalation nor oral administration caused neoplasms (tun assays. SAS does not impair development of the foetus. Fertility were not affected. For Synthetic Amorphous Silica (SAS) Repeated dose toxicity Oral (rat), 2 weeks to 6 months, no significant treatment-related a Inhalation (rat), 13 weeks, Lowest Observed Effect Level (LOEL) days, LOEL = 1 mg/m3 based on reversible effects in the lungs a For silane treated synthetic amorphous silica: Repeated dose toxicity: oral (rat), 28-d, diet, no significant treatment There is no evidence of cancer or other long-term respiratory hee SAS. Respiratory symptoms in SAS workers have been shown to function values and chest radiographs are not adversely affected X	AS) dust, it dissolves in th comulation in the body. F expected to be broken do cted subcutaneously are s chemical structure and av- hat are formed are elimin- ignificantly influenced by try inhalation. Adverse effec cles generated to meet the re used for human risk ass it is not a sensitiser. of toxicity when SAS is sw mals (increases in lung inf city studies have been cor served adverse effect lev IOAELs) were between 0. varticles administered per nours). SAS is not mutage was not specifically studies adverse effects at doses or =1.3 mg/m3 based on mil nd effects (for example, s o correlate with smoking bi by long-term exposure to Carcinogenicity Reproductivity	e lung fluid and is rapidly eliminated. If swallowed, the following absorption across the gut, SAS is eliminated own (metabolised) in mammals. soccurs. Intestinal absorption has not been calculated, subjected to rapid dissolution and removal. There is r ailable data. In contrast to crystalline silica, SAS is ated via the urinary tract without modification. the physical and chemical properties, particularly tho cts, including suffocation, that have been reported a required test atmosphere. These results are not sessment. Though repeated exposure of the skin may vallowed or upon skin contact. lammation, cell injury and lung collagen content), all nducted with SAS in a number of species, at airborne els (LOAELs) were typically in the range of 1 to 50 5 and 10 mg/m3. The difference in values may be unit dose. In general, as particle size decreases so nic in vitro. No genotoxicity was detected in in vivo id, but the reproductive organs in long-term studies f up to 8% silica in the diet. d reversible effects in the lungs. Inhalation (rat), 90 <i>rity.</i> s at the doses tested. ilicosis) in workers employed in the manufacture of ut not with SAS exposure, while serial pulmonary SAS.

SECTION 12 Ecological information

Toxicity

lable point 0 0	Not Available Test Duration (hr) 72h 48h		Not Available	Value	Not Available	Not Available Source
0	72h					Source
0		AI	and an other equatio planta			
	48h		gae or other aquatic plants	20.76-36	6.17mg/L	4
0		С	rustacea	0.00439	-0.00565mg/l	4
0	96h	AI	gae or other aquatic plants	1110.36	mg/L	4
0	96h	Fi	sh	1000mg	/I	4
C(ECx)	6h	Fi	sh	0.001mg	g/l	4
point	Test Duration (hr)		Species	Val	ue	Sourc
0	96h	I	Fish	372	2.9-450.7mg/l	4
point	Test Duration (hr)		Species		Value	Source
lable	Not Available		Not Available		Not Available	Not Availabl
	Point 0 point 1 point 1 lable 1 ted from	EC(ECx) 6h point Test Duration (hr) 0 96h point Test Duration (hr) ilable Not Available ited from 1. IUCLID Toxicity Data 2. Europe E	EC(ECx) 6h Fis point Test Duration (hr) 9 0 96h Fis point Test Duration (hr) Fis point Test Duration (hr) Fis point Test Duration (hr) Fis point Not Available Fis ted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Fis	EC(ECx) 6h Fish point Test Duration (hr) Species 0 96h Fish point Test Duration (hr) Species able Not Available Not Available Not Available Not Available Not Available	EC(ECx) 6h Fish 0.001 mg point Test Duration (hr) Species Val 0 96h Fish 372 point Test Duration (hr) Species Val 0 96h Not Available Not Available Not Available Not Available Not Available Not Available	EC(ECx) 6h Fish 0.001mg/l point Test Duration (hr) Species Value 0 96h Fish 372.9-450.7mg/l point Test Duration (hr) Species Value Not Available Not Available Not

DO NOT discharge into sewer or waterways.

Persistence and degradability		
Ingredient	Persistence: Water/Soil	Persistence: Air
sodium chloride	LOW	LOW
Bioaccumulative potential		
Ingredient	Bioaccumulation	

Ingredient	Divaccumulation
sodium chloride	LOW (LogKOW = 0.5392)
Mobility in soil	

Ingredient	Mobility
sodium chloride	LOW (KOC = 14.3)

SECTION 13 Disposal considerations

Waste treatment methods		
Product / Packaging disposal	 Recycle wherever possible or consult manufacturer for recycling options. Consult State Land Waste Management Authority for disposal. Bury residue in an authorised landfill. Recycle containers if possible, or dispose of in an authorised landfill. 	

SECTION 14 Transport information

Labels Required

Marine	Pollutant	NO

Shipping container and transport vehicle placarding and labeling may vary from the below information. Products that are regulated for transport will be packaged and marked as Dangerous Goods in Limited Quantities according to US DOT, IATA and IMDG regulations. In case of reshipment, it is the responsibility of the shipper to determine the appropriate labels and markings in accordance with applicable transport regulations.

Land transport (DOT): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
sodium chloride	Not Available
erythromycin phosphate	Not Available
silica amorphous, fumed, crystalline free	Not Available

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
sodium chloride	Not Available
erythromycin phosphate	Not Available
silica amorphous, fumed, crystalline free	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

sodium chloride is found on the following regulatory lists

US DOE Temporary Emergency Exposure Limits (TEELs)

erythromycin phosphate is found on the following regulatory lists Not Applicable

silica amorphous, fumed, crystalline free is found on the following regulatory lists

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

US - Alaska Air Quality Control - Concentrations Triggering an Air Quality Episode for Air Pollutants Other Than PM-2.5

US - Massachusetts - Right To Know Listed Chemicals

US DOE Temporary Emergency Exposure Limits (TEELs)

Federal Regulations

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Section 311/312 hazard categories

Flammable (Gases, Aerosols, Liquids, or Solids)	No
Gas under pressure	No
Explosive	No
Self-heating	No
Pyrophoric (Liquid or Solid)	No
Pyrophoric Gas	No
Corrosive to metal	No
Oxidizer (Liquid, Solid or Gas)	No
Organic Peroxide	No
Self-reactive	No
In contact with water emits flammable gas	No
Combustible Dust	No
Carcinogenicity	No
Acute toxicity (any route of exposure)	No
Reproductive toxicity	No
Skin Corrosion or Irritation	Yes
Respiratory or Skin Sensitization	No
Serious eye damage or eye irritation	Yes
Specific target organ toxicity (single or repeated exposure)	No
Aspiration Hazard	No
Germ cell mutagenicity	No
Simple Asphyxiant	No
Hazards Not Otherwise Classified	No

US. EPA CERCLA Hazardous Substances and Reportable Quantities (40 CFR 302.4)

None Reported

State Regulations

US. California Proposition 65

None Reported

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	No (erythromycin phosphate)
Canada - DSL	No (erythromycin phosphate)
Canada - NDSL	No (sodium chloride; erythromycin phosphate; silica amorphous, fumed, crystalline free)

US Toxic Substances Control Act (TSCA) - Chemical Substance Inventory

US NIOSH Recommended Exposure Limits (RELs) US OSHA Permissible Exposure Limits (PELs) Table Z-1 US OSHA Permissible Exposure Limits (PELs) Table Z-3

National Inventory	Status		
China - IECSC	No (erythromycin phosphate)		
Europe - EINEC / ELINCS / NLP	No (silica amorphous, fumed, crystalline free)		
Japan - ENCS	No (erythromycin phosphate)		
Korea - KECI	No (erythromycin phosphate)		
New Zealand - NZIoC	No (erythromycin phosphate)		
Philippines - PICCS	No (erythromycin phosphate)		
USA - TSCA	No (erythromycin phosphate; silica amorphous, fumed, crystalline free)		
Taiwan - TCSI	No (erythromycin phosphate)		
Mexico - INSQ	No (erythromycin phosphate)		
Vietnam - NCI	No (erythromycin phosphate)		
Russia - FBEPH	No (erythromycin phosphate)		
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.		

SECTION 16 Other information

Revision Date	03/10/2023
Initial Date	01/05/2006

SDS Version Summary

Version	Date of Update	Sections Updated
6.1	11/01/2019	One-off system update. NOTE: This may or may not change the GHS classification
7.1	03/10/2023	Classification change due to full database hazard calculation/update.

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC - TWA: Permissible Concentration-Time Weighted Average PC - STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancel ACGIH: American Conference of Governmental Industrial Hygienists STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure Limit, IDLH: Immediately Dangerous to Life or Health Concentrations ES: Exposure Standard OSF: Odour Safety Factor NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value BCF: BioConcentration Factors BEI: Biological Exposure Index AIIC: Australian Inventory of Industrial Chemicals DSL: Domestic Substances List NDSL: Non-Domestic Substances List IECSC: Inventory of Existing Chemical Substance in China EINECS: European INventory of Existing Commercial chemical Substances ELINCS: European List of Notified Chemical Substances NLP: No-Longer Polymers ENCS: Existing and New Chemical Substances Inventory KECI: Korea Existing Chemicals Inventory NZIoC: New Zealand Inventory of Chemicals PICCS: Philippine Inventory of Chemicals and Chemical Substances TSCA: Toxic Substances Control Act TCSI: Taiwan Chemical Substance Inventory INSQ: Inventario Nacional de Sustancias Químicas NCI: National Chemical Inventory FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.